MXPA03010747A - Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. - Google Patents
Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral.Info
- Publication number
- MXPA03010747A MXPA03010747A MXPA03010747A MXPA03010747A MXPA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A MX PA03010747 A MXPA03010747 A MX PA03010747A
- Authority
- MX
- Mexico
- Prior art keywords
- antibodies
- immunospecifically bind
- relates
- methods
- trail receptors
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2878—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the NGF-receptor/TNF-receptor superfamily, e.g. CD27, CD30, CD40, CD95
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
- C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
- C07K2317/565—Complementarity determining region [CDR]
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
- C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
- C07K2317/622—Single chain antibody (scFv)
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Immunology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Biochemistry (AREA)
- Virology (AREA)
- Cell Biology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- Endocrinology (AREA)
- AIDS & HIV (AREA)
- Reproductive Health (AREA)
- Oncology (AREA)
- Pulmonology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Neurosurgery (AREA)
- Neurology (AREA)
- Dermatology (AREA)
- Peptides Or Proteins (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
La presente invencion se refiere a anticuerpos y moleculas relacionadas que se unen inmunoespecificamente a receptor de TRAIL, TR4; dichos anticuerpos tienen usos, por ejemplo, en la prevencion y tratamiento de canceres y otros trastornos proliferativos; la invencion tambien se refiere a moleculas de acido nucleico que codifican anticuerpos anti-TR4, vectores y celulas hospedero que contienen estos acidos nucleicos, y metodos para producir los mismos; la presente invencion se refiere a metodos y composiciones para prevenir, detectar, diagnosticar, tratar o aliviar una enfermedad o trastorno, especialmente cancer y otros trastornos hiperproliferativos, que comprende administrar a un animal, preferiblemente a un humano, una cantidad efectiva de uno o mas anticuerpos o fragmentos o variantes de los mismos, o moleculas relacionadas, que se unen inmunoespecificamente al receptor de TRAIL, TR4.
Applications Claiming Priority (10)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US29347301P | 2001-05-25 | 2001-05-25 | |
US29498101P | 2001-06-04 | 2001-06-04 | |
US30917601P | 2001-08-02 | 2001-08-02 | |
US32380701P | 2001-09-21 | 2001-09-21 | |
US32736401P | 2001-10-09 | 2001-10-09 | |
US33104401P | 2001-11-07 | 2001-11-07 | |
US33131001P | 2001-11-14 | 2001-11-14 | |
US34123701P | 2001-12-20 | 2001-12-20 | |
US36986002P | 2002-04-05 | 2002-04-05 | |
PCT/US2002/014268 WO2002097033A2 (en) | 2001-05-25 | 2002-05-07 | Antibodies that immunospecifically bind to trail receptors |
Publications (1)
Publication Number | Publication Date |
---|---|
MXPA03010747A true MXPA03010747A (es) | 2004-03-02 |
Family
ID=50151047
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MXPA03010747A MXPA03010747A (es) | 2001-05-25 | 2002-05-07 | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. |
Country Status (14)
Country | Link |
---|---|
US (1) | US7064189B2 (es) |
EP (1) | EP1572874B1 (es) |
JP (2) | JP4309758B2 (es) |
KR (1) | KR100942393B1 (es) |
CN (1) | CN100594935C (es) |
AU (1) | AU2002309647C1 (es) |
CA (1) | CA2446723C (es) |
DK (1) | DK1572874T3 (es) |
ES (1) | ES2437992T3 (es) |
HK (1) | HK1075470A1 (es) |
MX (1) | MXPA03010747A (es) |
NZ (1) | NZ529359A (es) |
PT (1) | PT1572874E (es) |
WO (1) | WO2002097033A2 (es) |
Families Citing this family (37)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2004529610A (ja) * | 2000-10-13 | 2004-09-30 | ユーエイビー リサーチ ファンデーション | ヒト抗上皮増殖因子受容体一本鎖抗体 |
US20060062786A1 (en) * | 2000-11-08 | 2006-03-23 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20030228309A1 (en) * | 2000-11-08 | 2003-12-11 | Theodora Salcedo | Antibodies that immunospecifically bind to TRAIL receptors |
US7361341B2 (en) * | 2001-05-25 | 2008-04-22 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to trail receptors |
US7348003B2 (en) | 2001-05-25 | 2008-03-25 | Human Genome Sciences, Inc. | Methods of treating cancer using antibodies that immunospecifically bind to TRAIL receptors |
CN100594935C (zh) * | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
US20050214209A1 (en) * | 2001-05-25 | 2005-09-29 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
US20090226429A1 (en) * | 2001-05-25 | 2009-09-10 | Human Genome Sciences, Inc. | Antibodies That Immunospecifically Bind to TRAIL Receptors |
US20050129616A1 (en) * | 2001-05-25 | 2005-06-16 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to TRAIL receptors |
AU2002366430B2 (en) | 2001-07-03 | 2008-09-18 | Genentech, Inc. | Human DR4 antibodies and uses thereof |
CA2471140A1 (en) * | 2001-12-20 | 2003-07-03 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
WO2005016236A2 (en) * | 2003-05-06 | 2005-02-24 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
WO2003097698A1 (en) * | 2002-05-17 | 2003-11-27 | Fusion Antibodies Limited | Treatment of cancer by the use of anti fas antibody |
CA2494372C (en) * | 2002-08-15 | 2013-05-28 | Human Genome Sciences, Inc. | Antibodies that immunospecifically bind to trail receptors |
JP2004279086A (ja) | 2003-03-13 | 2004-10-07 | Konica Minolta Holdings Inc | 放射線画像変換パネル及び放射線画像変換パネルの製造方法 |
SI1606318T1 (sl) * | 2003-03-26 | 2009-12-31 | Apogenix Gmbh | Izboljšani Fc fuzijski proteini |
US7407767B2 (en) * | 2003-04-16 | 2008-08-05 | Ono Pharmaceutical Co., Ltd. | Method of screening remedy for heart disease and medicinal composition for treating heart disease |
JPWO2005056605A1 (ja) * | 2003-12-12 | 2007-12-06 | 中外製薬株式会社 | 3量体以上の受容体を認識する改変抗体 |
WO2005067980A2 (en) * | 2004-01-12 | 2005-07-28 | Pointilliste, Inc. | Design of therapeutics and therapeutics |
WO2006017859A2 (en) | 2004-08-06 | 2006-02-16 | Genentech, Inc. | Assays and methods using biomarkers |
ATE508205T1 (de) | 2004-08-06 | 2011-05-15 | Genentech Inc | Tests und verfahren unter verwendung von biomarkern |
JO3000B1 (ar) | 2004-10-20 | 2016-09-05 | Genentech Inc | مركبات أجسام مضادة . |
US8029783B2 (en) | 2005-02-02 | 2011-10-04 | Genentech, Inc. | DR5 antibodies and articles of manufacture containing same |
US9493569B2 (en) | 2005-03-31 | 2016-11-15 | Chugai Seiyaku Kabushiki Kaisha | Structural isomers of sc(Fv)2 |
CN101262885B (zh) | 2005-06-10 | 2015-04-01 | 中外制药株式会社 | 含有sc(Fv)2的药物组合物 |
CN101237890A (zh) | 2005-06-10 | 2008-08-06 | 中外制药株式会社 | 含有葡甲胺的蛋白质制剂的稳定剂及其利用 |
CA2619842A1 (en) | 2005-08-16 | 2007-02-22 | Genentech, Inc. | Apoptosis sensitivity to ap02l/trail by testing for 'galnac-t14 expression in cells/tissues |
US7776605B2 (en) | 2006-10-26 | 2010-08-17 | Abbott Laboratories | Assay for cardiac troponin autoantibodies |
MX2009004460A (es) * | 2006-10-26 | 2009-07-09 | Abbott Lab | Inmunoensayo de analitos en muestras que contienen anticuerpos anti-analito endogenos. |
US20080305512A1 (en) * | 2006-10-26 | 2008-12-11 | Mattingly Phillip G | Assay for cardiac troponin autoantibodies |
WO2010111842A1 (zh) * | 2009-04-03 | 2010-10-07 | 中国医学科学院基础医学研究所 | 抗人死亡受体dr5单克隆抗体ad5-10所识别的抗原决定簇、其衍生物及其用途 |
JP2013507124A (ja) * | 2009-10-09 | 2013-03-04 | アナフォア インコーポレイテッド | Il−23rを結合するポリペプチド |
EP2684896A1 (en) | 2012-07-09 | 2014-01-15 | International-Drug-Development-Biotech | Anti-DR5 family antibodies, bispecific or multivalent anti-DR5 family antibodies and methods of use thereof |
EP3305812B1 (en) | 2013-03-14 | 2020-06-17 | Bristol-Myers Squibb Company | Combination of dr5 agonist and anti-pd-1 antagonist and methods of use |
CN107108736B (zh) * | 2014-11-14 | 2021-07-23 | 北京先通生物医药技术有限公司 | Trail受体结合剂及其用途 |
MA43365A (fr) | 2015-12-01 | 2018-10-10 | Genmab Bv | Anticorps anti-dr5 et procédés d'utilisation de ceux-ci |
CN112805299A (zh) * | 2018-10-05 | 2021-05-14 | 西雅图儿童医院以西雅图儿童研究机构名义经营 | 针对原发性免疫缺陷、胱氨酸病和威尔逊病的新生儿筛查 |
Family Cites Families (172)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US4179337A (en) * | 1973-07-20 | 1979-12-18 | Davis Frank F | Non-immunogenic polypeptides |
US4002531A (en) | 1976-01-22 | 1977-01-11 | Pierce Chemical Company | Modifying enzymes with polyethylene glycol and product produced thereby |
US4444887A (en) | 1979-12-10 | 1984-04-24 | Sloan-Kettering Institute | Process for making human antibody producing B-lymphocytes |
US4716111A (en) | 1982-08-11 | 1987-12-29 | Trustees Of Boston University | Process for producing human antibodies |
US4741900A (en) | 1982-11-16 | 1988-05-03 | Cytogen Corporation | Antibody-metal ion complexes |
GB8308235D0 (en) | 1983-03-25 | 1983-05-05 | Celltech Ltd | Polypeptides |
US4816567A (en) | 1983-04-08 | 1989-03-28 | Genentech, Inc. | Recombinant immunoglobin preparations |
US4496654A (en) * | 1983-04-08 | 1985-01-29 | Quidel | Detection of HCG with solid phase support having avidin coating |
JPS60150456A (ja) | 1984-01-19 | 1985-08-08 | Diesel Kiki Co Ltd | 内燃機関用燃料噴射装置 |
US5807715A (en) | 1984-08-27 | 1998-09-15 | The Board Of Trustees Of The Leland Stanford Junior University | Methods and transformed mammalian lymphocyte cells for producing functional antigen-binding protein including chimeric immunoglobulin |
US4631211A (en) | 1985-03-25 | 1986-12-23 | Scripps Clinic & Research Foundation | Means for sequential solid phase organic synthesis and methods using the same |
WO1986005807A1 (en) | 1985-04-01 | 1986-10-09 | Celltech Limited | Transformed myeloma cell-line and a process for the expression of a gene coding for a eukaryotic polypeptide employing same |
US4980286A (en) | 1985-07-05 | 1990-12-25 | Whitehead Institute For Biomedical Research | In vivo introduction and expression of foreign genetic material in epithelial cells |
US4676980A (en) | 1985-09-23 | 1987-06-30 | The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services | Target specific cross-linked heteroantibodies |
GB8601597D0 (en) | 1986-01-23 | 1986-02-26 | Wilson R H | Nucleotide sequences |
US5225539A (en) | 1986-03-27 | 1993-07-06 | Medical Research Council | Recombinant altered antibodies and methods of making altered antibodies |
GB8607679D0 (en) | 1986-03-27 | 1986-04-30 | Winter G P | Recombinant dna product |
US4946778A (en) * | 1987-09-21 | 1990-08-07 | Genex Corporation | Single polypeptide chain binding molecules |
EP0307434B2 (en) | 1987-03-18 | 1998-07-29 | Scotgen Biopharmaceuticals, Inc. | Altered antibodies |
US4994560A (en) | 1987-06-24 | 1991-02-19 | The Dow Chemical Company | Functionalized polyamine chelants and radioactive rhodium complexes thereof for conjugation to antibodies |
US5489425A (en) | 1987-06-24 | 1996-02-06 | The Dow Chemical Company | Functionalized polyamine chelants |
GB8717430D0 (en) | 1987-07-23 | 1987-08-26 | Celltech Ltd | Recombinant dna product |
GB8725529D0 (en) | 1987-10-30 | 1987-12-02 | Delta Biotechnology Ltd | Polypeptides |
GB8809129D0 (en) | 1988-04-18 | 1988-05-18 | Celltech Ltd | Recombinant dna methods vectors and host cells |
AU631802B2 (en) | 1988-06-14 | 1992-12-10 | Cetus Oncology Corporation | Coupling agents and sterically hindered disulfide linked conjugates prepared therefrom |
AU634167B2 (en) | 1988-06-24 | 1993-02-18 | Dow Chemical Company, The | Macrocyclic bifunctional chelants, complexes thereof and their antibody conjugates |
US5756065A (en) | 1988-06-24 | 1998-05-26 | The Dow Chemical Company | Macrocyclic tetraazacyclododecane conjugates and their use as diagnostic and therapeutic agents |
US5274119A (en) | 1988-07-01 | 1993-12-28 | The Dow Chemical Company | Vicinal diols |
EP0768377A1 (en) | 1988-09-02 | 1997-04-16 | Protein Engineering Corporation | Generation and selection of recombinant varied binding proteins |
US5223409A (en) | 1988-09-02 | 1993-06-29 | Protein Engineering Corp. | Directed evolution of novel binding proteins |
US5349052A (en) | 1988-10-20 | 1994-09-20 | Royal Free Hospital School Of Medicine | Process for fractionating polyethylene glycol (PEG)-protein adducts and an adduct for PEG and granulocyte-macrophage colony stimulating factor |
KR900005995A (ko) | 1988-10-31 | 1990-05-07 | 우메모또 요시마사 | 변형 인터류킨-2 및 그의 제조방법 |
US5696239A (en) | 1988-10-31 | 1997-12-09 | The Dow Chemical Company | Conjugates possessing ortho ligating functionality and complexes thereof |
US5342604A (en) | 1988-10-31 | 1994-08-30 | The Dow Chemical Company | Complexes possessing ortho ligating functionality |
CA2006596C (en) | 1988-12-22 | 2000-09-05 | Rika Ishikawa | Chemically-modified g-csf |
US5530101A (en) | 1988-12-28 | 1996-06-25 | Protein Design Labs, Inc. | Humanized immunoglobulins |
US5324844A (en) | 1989-04-19 | 1994-06-28 | Enzon, Inc. | Active carbonates of polyalkylene oxides for modification of polypeptides |
EP0394827A1 (en) | 1989-04-26 | 1990-10-31 | F. Hoffmann-La Roche Ag | Chimaeric CD4-immunoglobulin polypeptides |
US5766883A (en) | 1989-04-29 | 1998-06-16 | Delta Biotechnology Limited | Polypeptides |
ZA902949B (en) | 1989-05-05 | 1992-02-26 | Res Dev Foundation | A novel antibody delivery system for biological response modifiers |
US5808003A (en) | 1989-05-26 | 1998-09-15 | Perimmune Holdings, Inc. | Polyaminocarboxylate chelators |
US5112946A (en) | 1989-07-06 | 1992-05-12 | Repligen Corporation | Modified pf4 compositions and methods of use |
FR2650598B1 (fr) | 1989-08-03 | 1994-06-03 | Rhone Poulenc Sante | Derives de l'albumine a fonction therapeutique |
US5073627A (en) | 1989-08-22 | 1991-12-17 | Immunex Corporation | Fusion proteins comprising GM-CSF and IL-3 |
US5436146A (en) | 1989-09-07 | 1995-07-25 | The Trustees Of Princeton University | Helper-free stocks of recombinant adeno-associated virus vectors |
GB8924021D0 (en) | 1989-10-25 | 1989-12-13 | Celltech Ltd | Recombinant dna method and vectors for the use therein |
WO1991006570A1 (en) | 1989-10-25 | 1991-05-16 | The University Of Melbourne | HYBRID Fc RECEPTOR MOLECULES |
GB8928874D0 (en) | 1989-12-21 | 1990-02-28 | Celltech Ltd | Humanised antibodies |
US5780225A (en) | 1990-01-12 | 1998-07-14 | Stratagene | Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules |
AU7247191A (en) | 1990-01-11 | 1991-08-05 | Molecular Affinities Corporation | Production of antibodies using gene libraries |
EP1690935A3 (en) | 1990-01-12 | 2008-07-30 | Abgenix, Inc. | Generation of xenogeneic antibodies |
US5314995A (en) | 1990-01-22 | 1994-05-24 | Oncogen | Therapeutic interleukin-2-antibody based fusion proteins |
FI90454C (fi) | 1990-02-22 | 1994-02-10 | Patenttitoimisto T Poutanen Oy | Menetelmä naulalevykattotuolin valmistamiseksi |
WO1991014438A1 (en) | 1990-03-20 | 1991-10-03 | The Trustees Of Columbia University In The City Of New York | Chimeric antibodies with receptor binding ligands in place of their constant region |
US5427908A (en) | 1990-05-01 | 1995-06-27 | Affymax Technologies N.V. | Recombinant library screening methods |
US5349053A (en) * | 1990-06-01 | 1994-09-20 | Protein Design Labs, Inc. | Chimeric ligand/immunoglobulin molecules and their uses |
ES2251009T3 (es) | 1990-06-28 | 2006-04-16 | Sanofi-Aventis Deutschland Gmbh | Proteinas de fusion con partes de inmunoglobulinas, su preparacion y uso. |
GB9015198D0 (en) | 1990-07-10 | 1990-08-29 | Brien Caroline J O | Binding substance |
DE4025687A1 (de) | 1990-08-14 | 1992-02-20 | Ruetgerswerke Ag | Durch strahlung vernetzbare bindemittelgemische |
US5698426A (en) | 1990-09-28 | 1997-12-16 | Ixsys, Incorporated | Surface expression libraries of heteromeric receptors |
EP0553235A1 (en) | 1990-10-01 | 1993-08-04 | The University Of Connecticut | Targeting viruses and cells for selective internalization by cells |
CA2095836C (en) | 1990-11-09 | 1999-04-06 | Stephen D. Gillies | Cytokine immunoconjugates |
DK0564531T3 (da) | 1990-12-03 | 1998-09-28 | Genentech Inc | Berigelsesfremgangsmåde for variantproteiner med ændrede bindingsegenskaber |
JP3242916B2 (ja) | 1990-12-14 | 2001-12-25 | セル ジェネシス,インコーポレイティド | レセプター関連シグナル変換系のためのキメラ鎖 |
US5714711A (en) | 1990-12-31 | 1998-02-03 | Mei Corporation | Encapsulated propellant grain composition, method of preparation, article fabricated therefrom and method of fabrication |
CA2108147C (en) | 1991-04-10 | 2009-01-06 | Angray Kang | Heterodimeric receptor libraries using phagemids |
EP0510691B1 (en) | 1991-04-26 | 2004-11-03 | Osaka Bioscience Institute | DNA coding for human cell surface antigen |
CA2103064A1 (en) | 1991-05-14 | 1992-11-15 | George Y. Wu | Targeted delivery of genes encoding immunogenic proteins |
DE69233482T2 (de) | 1991-05-17 | 2006-01-12 | Merck & Co., Inc. | Verfahren zur Verminderung der Immunogenität der variablen Antikörperdomänen |
DE4119353C1 (es) | 1991-06-12 | 1992-12-17 | Deutsche Rockwool Mineralwoll Gmbh, 4390 Gladbeck, De | |
US5356603A (en) | 1991-06-17 | 1994-10-18 | Johnson Matthey Inc. | Method for the production of hydrocyanic acid using a corrugated catalyst |
IL99120A0 (en) | 1991-08-07 | 1992-07-15 | Yeda Res & Dev | Multimers of the soluble forms of tnf receptors,their preparation and pharmaceutical compositions containing them |
US5565332A (en) * | 1991-09-23 | 1996-10-15 | Medical Research Council | Production of chimeric antibodies - a combinatorial approach |
ES2227512T3 (es) | 1991-12-02 | 2005-04-01 | Medical Research Council | Produccion de anticuerpos contra auto-antigenos a partir de repertorios de segmentos de anticuerpos fijados en un fago. |
US5428139A (en) | 1991-12-10 | 1995-06-27 | The Dow Chemical Company | Bicyclopolyazamacrocyclophosphonic acid complexes for use as radiopharmaceuticals |
AU3434393A (en) | 1992-01-17 | 1993-08-03 | Regents Of The University Of Michigan, The | Targeted virus |
US5622929A (en) | 1992-01-23 | 1997-04-22 | Bristol-Myers Squibb Company | Thioether conjugates |
FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
US5447851B1 (en) | 1992-04-02 | 1999-07-06 | Univ Texas System Board Of | Dna encoding a chimeric polypeptide comprising the extracellular domain of tnf receptor fused to igg vectors and host cells |
WO1993020221A1 (en) | 1992-04-03 | 1993-10-14 | Young Alexander T | Gene therapy using targeted viral vectors |
ZA932522B (en) | 1992-04-10 | 1993-12-20 | Res Dev Foundation | Immunotoxins directed against c-erbB-2(HER/neu) related surface antigens |
US5505931A (en) | 1993-03-04 | 1996-04-09 | The Dow Chemical Company | Acid cleavable compounds, their preparation and use as bifunctional acid-labile crosslinking agents |
GB9214857D0 (en) | 1992-07-13 | 1992-08-26 | Medical Res Council | Human nucleic acid fragments and their use |
EP0652950B1 (en) | 1992-07-24 | 2007-12-19 | Amgen Fremont Inc. | Generation of xenogeneic antibodies |
WO1994004670A1 (en) | 1992-08-26 | 1994-03-03 | President And Fellows Of Harvard College | Use of the cytokine ip-10 as an anti-tumor agent |
US5639641A (en) | 1992-09-09 | 1997-06-17 | Immunogen Inc. | Resurfacing of rodent antibodies |
DE4233586A1 (de) | 1992-10-06 | 1994-04-07 | Bayer Ag | 3-Imino-3-alkoxy-propionsäurelactate und deren tautomere Acrylsäurelactate |
ES2157225T3 (es) | 1992-10-09 | 2001-08-16 | Advanced Tissue Sciences Inc | Celulas hepaticas de reserva. |
AU678787B2 (en) | 1992-10-23 | 1997-06-12 | Immunex Corporation | Methods of preparing soluble, oligomeric proteins |
EP0911413A3 (en) | 1992-12-03 | 2000-11-15 | Genzyme Corporation | Minimal adenovirus-based gene therapy vector |
US5441050A (en) | 1992-12-18 | 1995-08-15 | Neoprobe Corporation | Radiation responsive surgical instrument |
GB9317618D0 (en) | 1993-08-24 | 1993-10-06 | Royal Free Hosp School Med | Polymer modifications |
CA2174132A1 (en) | 1993-10-14 | 1995-04-20 | Immunex Corporation | Fas antagonists and uses thereof |
US5643575A (en) | 1993-10-27 | 1997-07-01 | Enzon, Inc. | Non-antigenic branched polymer conjugates |
US5565352A (en) | 1993-11-24 | 1996-10-15 | Arch Development Corporation | Deubiquitinating enzyme: compositions and methods |
JPH09506262A (ja) | 1993-12-08 | 1997-06-24 | ジェンザイム・コーポレイション | 特異的抗体の製造方法 |
JP2552425B2 (ja) | 1993-12-14 | 1996-11-13 | コナミ株式会社 | 実況中継機能付きゲーム機 |
PT744958E (pt) | 1994-01-31 | 2003-11-28 | Univ Boston | Bancos de anticorpos policlonais |
US5837458A (en) | 1994-02-17 | 1998-11-17 | Maxygen, Inc. | Methods and compositions for cellular and metabolic engineering |
US5605793A (en) | 1994-02-17 | 1997-02-25 | Affymax Technologies N.V. | Methods for in vitro recombination |
US5834252A (en) | 1995-04-18 | 1998-11-10 | Glaxo Group Limited | End-complementary polymerase reaction |
US5985660A (en) | 1994-06-15 | 1999-11-16 | Systemix, Inc. | Method of identifying biological response modifiers involved in dendritic and/or lymphoid progenitor cell proliferation and/or differentiation |
CN1117155C (zh) | 1994-07-29 | 2003-08-06 | 史密丝克莱恩比彻姆有限公司 | 新型化合物 |
CA2203655C (en) | 1994-11-07 | 2010-03-23 | Guo-Liang Yu | Tumor necrosis factor-gamma |
IL117175A (en) | 1995-02-20 | 2005-11-20 | Sankyo Co | Osteoclastogenesis inhibitory factor protein |
JP3521016B2 (ja) | 1995-03-27 | 2004-04-19 | 松下電器産業株式会社 | 直交周波数分割多重信号の受信方法および受信装置 |
US5516717A (en) | 1995-04-19 | 1996-05-14 | United Microelectronics Corporation | Method for manufacturing electrostatic discharge devices |
WO1996034095A1 (en) | 1995-04-27 | 1996-10-31 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptors |
EP0823941A4 (en) | 1995-04-28 | 2001-09-19 | Abgenix Inc | HUMAN ANTIBODIES DERIVED FROM IMMUNIZED XENO MOUSES |
AU5919096A (en) | 1995-05-08 | 1996-11-29 | Michel J. Hourani | Alkoxylated dimethylolpropionic acid modifier |
DE19523218A1 (de) | 1995-06-27 | 1997-01-02 | Schaeffler Waelzlager Kg | Hydraulisch betätigte Ausrückvorrichtung für eine Reibungskupplung |
JP4435304B2 (ja) | 1995-06-29 | 2010-03-17 | イミュネックス・コーポレーション | アポトーシスを誘導するサイトカイン |
GB9601081D0 (en) | 1995-10-06 | 1996-03-20 | Cambridge Antibody Tech | Specific binding members for human transforming growth factor beta;materials and methods |
JP2978435B2 (ja) | 1996-01-24 | 1999-11-15 | チッソ株式会社 | アクリロキシプロピルシランの製造方法 |
WO1997033899A1 (en) | 1996-03-14 | 1997-09-18 | Human Genome Sciences, Inc. | Apoptosis inducing molecule i |
DE19611367A1 (de) | 1996-03-22 | 1997-09-25 | Bayer Ag | Verfahren zur Herstellung Kohlenwasserstoff-getriebener Polyurethan-Hartschaumstoffe |
KR100497017B1 (ko) | 1996-03-22 | 2005-11-29 | 휴먼 게놈 사이언시즈, 인코포레이티드 | 고사유도분자ii |
KR20000004952A (ko) | 1996-03-27 | 2000-01-25 | 더블류. 하링, 지. 보이롤 | 혼합물로부터 다공성 중합체를 제조하는 방법 |
JP2000516474A (ja) | 1996-08-16 | 2000-12-12 | ヒューマン ジノーム サイエンシーズ,インコーポレイテッド | ヒトエンドカインα |
AU4055697A (en) | 1996-08-16 | 1998-03-06 | Schering Corporation | Mammalian cell surface antigens; related reagents |
JPH1057071A (ja) | 1996-08-19 | 1998-03-03 | Snow Brand Milk Prod Co Ltd | 新規dna及びそれを用いた蛋白質の製造方法 |
WO1998012344A1 (en) | 1996-09-18 | 1998-03-26 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
US5916771A (en) | 1996-10-11 | 1999-06-29 | Abgenix, Inc. | Production of a multimeric protein by cell fusion method |
ATE302272T1 (de) | 1996-10-25 | 2005-09-15 | Human Genome Sciences Inc | Neutrokin alpha |
EP0942968B1 (en) | 1996-12-03 | 2008-02-27 | Amgen Fremont Inc. | Fully human antibodies that bind EGFR |
DE69834027D1 (de) | 1997-01-14 | 2006-05-18 | Human Genome Sciences Inc | Tumor-nekrose-faktor rezeptor 5 |
KR20000070174A (ko) | 1997-01-14 | 2000-11-25 | 벤슨 로버트 에이치. | 종양 괴사 인자 수용체 6α 및 6β |
EP0857782A3 (en) | 1997-01-27 | 1999-12-22 | Smithkline Beecham Corporation | Novel mammalian DD-1 gene |
US6433147B1 (en) * | 1997-01-28 | 2002-08-13 | Human Genome Sciences, Inc. | Death domain containing receptor-4 |
PT1012274E (pt) * | 1997-01-28 | 2007-08-14 | Craig A Rosen | Receptor 4 contendo um domínio de morte (dm4; receptor de morte 4), membro da super-família do ftn e ligação a liart (ap02) |
WO1998032466A1 (en) | 1997-01-29 | 1998-07-30 | Polymasc Pharmaceuticals Plc | Pegylation process |
CA2221687A1 (en) | 1997-02-05 | 1998-08-05 | Smithkline Beecham Corporation | Tumor necrosis related receptor, tr5 |
US6072047A (en) * | 1997-02-13 | 2000-06-06 | Immunex Corporation | Receptor that binds trail |
US20010010924A1 (en) | 1997-03-14 | 2001-08-02 | Keith Charles Deen | Tumor necrosis factor related receptor, tr6 polynecleotides |
US6313269B1 (en) * | 1997-03-14 | 2001-11-06 | Smithkline Beecham Corporation | Tumor necrosis factor related receptor, TR6 |
US6872568B1 (en) * | 1997-03-17 | 2005-03-29 | Human Genome Sciences, Inc. | Death domain containing receptor 5 antibodies |
US7803615B1 (en) | 1997-03-17 | 2010-09-28 | Human Genome Sciences, Inc. | Death domain containing receptor 5 |
PT970126E (pt) | 1997-04-14 | 2001-10-30 | Micromet Ag | Novo metodo para a producao de receptores de antigenios anti-humanos e suas utilizacoes |
EP1007562A4 (en) | 1997-04-16 | 2000-09-27 | Millennium Pharm Inc | TANGO-63d AND TANGO-63e PROTEINS RELATED TO THE TUMOR NECROSIS FACTOR RECEPTOR |
JP2002514079A (ja) | 1997-05-01 | 2002-05-14 | アムジエン・インコーポレーテツド | キメラopgポリペプチド |
EP0975674B1 (en) | 1997-05-02 | 2005-08-17 | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services | Immunotoxins, comprising an onc protein, directed against malignant cells |
US6342369B1 (en) * | 1997-05-15 | 2002-01-29 | Genentech, Inc. | Apo-2-receptor |
EP1860187B1 (en) * | 1997-05-15 | 2011-07-13 | Genentech, Inc. | Apo-2 receptor |
AU7705198A (en) | 1997-05-30 | 1998-12-30 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor tr10 |
JP2002503963A (ja) | 1997-06-11 | 2002-02-05 | ヒューマン・ジェノム・サイエンシズ・インコーポレイテッド | ヒト腫瘍壊死因子受容体tr9 |
AU740227B2 (en) | 1997-06-18 | 2001-11-01 | Genentech Inc. | Apo-2DcR |
CA2294704A1 (en) | 1997-06-26 | 1999-01-07 | Immunex Corporation | Protein that binds trail |
AU8400398A (en) | 1997-07-11 | 1999-02-08 | Trustees Of The University Of Pennsylvania, The | Nucleic acid encoding a novel chemotherapy-induced protein, and methods of use |
EP0998561A4 (en) | 1997-07-15 | 2004-08-18 | Immunex Corp | RECEPTOR DES TRAIL PROTEIN |
CA2301202A1 (en) | 1997-08-15 | 1999-02-25 | Idun Pharmaceuticals, Inc. | Trail receptors, nucleic acids encoding the same, and methods of use thereof |
ES2331900T3 (es) | 1997-08-26 | 2010-01-19 | Genentech, Inc. | Receptor rtd. |
WO1999011791A2 (en) | 1997-09-05 | 1999-03-11 | University Of Washington | Tumor necrosis factor family receptors and ligands, encoding nucleic acids and related binding agents |
EP1012179A2 (en) | 1997-09-12 | 2000-06-28 | Apotech R&D S.A. | Cysteine rich receptors: trail |
WO1999023105A1 (en) | 1997-11-03 | 1999-05-14 | Human Genome Sciences, Inc. | Vegi, an inhibitor of angiogenesis and tumor growth |
AU2338299A (en) * | 1998-01-26 | 1999-08-09 | Genentech Inc. | Antibodies to death receptor 4 (dr4) and uses thereof |
US6790823B1 (en) | 1998-04-23 | 2004-09-14 | Amgen Inc. | Compositions and methods for the prevention and treatment of cardiovascular diseases |
WO2000008155A2 (en) | 1998-08-07 | 2000-02-17 | Incyte Pharmaceuticals, Inc. | Human receptor-associated proteins |
AU6006099A (en) | 1998-10-09 | 2000-05-01 | Sankyo Company Limited | Preventives or remedies for cachexia |
DE19856878A1 (de) | 1998-12-10 | 2000-06-15 | Inst Polymerforschung Dresden | Härtbare uretdiongruppenhaltige Massen und ein Verfahren zu ihrer Herstellung und Verarbeitung sowie ihre Verwendung |
WO2000050597A2 (en) | 1999-02-23 | 2000-08-31 | Human Genome Sciences, Inc. | Neutrokine-alpha and neutrokine-alpha splice variant |
AU3881100A (en) | 1999-03-15 | 2000-10-04 | Human Genome Sciences, Inc. | Human tumor necrosis factor receptor-like genes |
JP2002543151A (ja) | 1999-05-04 | 2002-12-17 | ヒューマン ジノーム サイエンシーズ, インコーポレイテッド | 死ドメイン含有レセプター5 |
EP1178828A4 (en) | 1999-05-06 | 2004-10-13 | Human Genome Sciences Inc | RECEPTOR CONTAINING "DEATH DOMAIN" |
WO2000071150A1 (en) | 1999-05-20 | 2000-11-30 | Human Genome Sciences, Inc. | Tumor necrosis factor receptor 5 |
CA2372246A1 (en) | 1999-05-28 | 2000-12-07 | Craig A. Rosen | Human tumor necrosis factor receptor tr10 |
ES2325305T3 (es) * | 1999-05-28 | 2009-09-01 | Genentech, Inc. | Anticuerpos dr4 quimericos y usos de los mismos. |
WO2000075191A2 (en) | 1999-06-09 | 2000-12-14 | Genentech, Inc. | Apo-2L RECEPTOR AGONIST AND CPT-11 SYNERGISM |
AU6343400A (en) | 1999-07-09 | 2001-01-30 | Genaissance Pharmaceuticals, Inc. | Drug target isogenes: polymorphisms in the osteoclastogenesis inhibitory factor gene |
WO2001003719A2 (en) | 1999-07-09 | 2001-01-18 | Amgen Inc. | Combination therapy for conditions leading to bone loss |
TWI318983B (en) | 2000-05-02 | 2010-01-01 | Uab Research Foundation | An antibody selective for a tumor necrosis factor-related apoptosis-inducing ligand receptor and uses thereof |
DE60143798D1 (de) * | 2000-06-16 | 2011-02-17 | Cambridge Antibody Tech | Immunspezifisch bindende antikörper gegen blys |
CN100594935C (zh) * | 2001-05-25 | 2010-03-24 | 人体基因组科学有限公司 | 免疫特异性结合trail受体的抗体 |
-
2002
- 2002-05-07 CN CN02814904A patent/CN100594935C/zh not_active Expired - Lifetime
- 2002-05-07 CA CA2446723A patent/CA2446723C/en not_active Expired - Lifetime
- 2002-05-07 JP JP2003500202A patent/JP4309758B2/ja not_active Expired - Lifetime
- 2002-05-07 WO PCT/US2002/014268 patent/WO2002097033A2/en active Application Filing
- 2002-05-07 MX MXPA03010747A patent/MXPA03010747A/es active IP Right Grant
- 2002-05-07 NZ NZ529359A patent/NZ529359A/en not_active IP Right Cessation
- 2002-05-07 PT PT27366616T patent/PT1572874E/pt unknown
- 2002-05-07 EP EP02736661.6A patent/EP1572874B1/en not_active Expired - Lifetime
- 2002-05-07 AU AU2002309647A patent/AU2002309647C1/en not_active Ceased
- 2002-05-07 US US10/139,785 patent/US7064189B2/en not_active Expired - Lifetime
- 2002-05-07 DK DK02736661.6T patent/DK1572874T3/da active
- 2002-05-07 KR KR1020037015417A patent/KR100942393B1/ko active IP Right Grant
- 2002-05-07 ES ES02736661.6T patent/ES2437992T3/es not_active Expired - Lifetime
-
2005
- 2005-11-01 HK HK05109696.3A patent/HK1075470A1/xx not_active IP Right Cessation
-
2008
- 2008-11-13 JP JP2008291575A patent/JP2009062393A/ja active Pending
Also Published As
Publication number | Publication date |
---|---|
JP2009062393A (ja) | 2009-03-26 |
KR20040003015A (ko) | 2004-01-07 |
US20030190685A1 (en) | 2003-10-09 |
ES2437992T3 (es) | 2014-01-15 |
AU2002309647B2 (en) | 2008-01-24 |
KR100942393B1 (ko) | 2010-02-17 |
DK1572874T3 (da) | 2013-12-16 |
CA2446723A1 (en) | 2002-12-05 |
PT1572874E (pt) | 2013-12-11 |
CN1635908A (zh) | 2005-07-06 |
WO2002097033A2 (en) | 2002-12-05 |
AU2002309647C1 (en) | 2008-09-11 |
WO2002097033A3 (en) | 2005-10-20 |
EP1572874A4 (en) | 2006-05-31 |
EP1572874A2 (en) | 2005-09-14 |
JP2005515963A (ja) | 2005-06-02 |
CN100594935C (zh) | 2010-03-24 |
HK1075470A1 (en) | 2005-12-16 |
NZ529359A (en) | 2007-04-27 |
JP4309758B2 (ja) | 2009-08-05 |
US7064189B2 (en) | 2006-06-20 |
EP1572874B1 (en) | 2013-09-18 |
CA2446723C (en) | 2014-01-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
MXPA03010747A (es) | Anticuerpos que se unen inmunoespecificamente a receptores de ligando inductor de apoptosis relacionado con factor de necrosis tumoral. | |
WO2003054216A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
MXPA02012434A (es) | Anticuerpos que se unen inmunoespecificamente a estimulador de linfocitos ii. | |
DE60028970D1 (de) | An her2 bindende peptidverbindungen | |
EP1401870A4 (en) | ANTIBODIES AGAINST TUMOR NECROSIS FACTOR DELTA (APRIL) | |
WO2003055979A3 (en) | ANTIBODIES THAT IMMUNOSPECIFICALLY BIND TO BLyS | |
WO2001055448A8 (en) | Nucleic acids, proteins, and antibodies | |
WO2004013287A3 (en) | Antibodies against c3a receptor | |
WO2001059063A3 (en) | Nucleic acids, proteins, and antibodies | |
WO2003089575A3 (en) | Antibodies that specifically bind to tl5 | |
WO2005016236A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003085093A3 (en) | Antibodies that specifically bind to gmad | |
WO2004003144A3 (en) | Antibodies that specifically bind to reg iv | |
MXPA03003902A (es) | Polipeptidos de proquineticina, composiciones relacionadas y metodos. | |
WO2003102136A3 (en) | Antibodies that specifically bind to neurokinin b | |
WO2004016753A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2002079377A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
WO2003042367A3 (en) | Antibodies that immunospecifically bind to trail receptors | |
ATE518884T1 (de) | Spezifisch an chemokin beta-4 bindende antikörper | |
IL207012A0 (en) | Diagnosis and therapy of cancer using sgp28-related molecules | |
WO2003086301A3 (en) | Antibodies that specifically bind to tr2 | |
WO2005018536A3 (en) | Agonist antibodies that specifically bind the glucagon like peptide-1 receptor | |
WO2002100343A3 (en) | N-terminally truncated galectin-3 and antibodies for treating cancer | |
CY1114921T1 (el) | Αντισωματα που δεσμευονται ανοσοειδικα στους trail υποδοχεις | |
WO2001055313A3 (en) | Nucleic acids, proteins, and antibodies |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |